

WUENIC Talking Points: Greece 🇬🇷

Revision Year: 2025

Contents

Overview	2
DTP1: Reaching zero-dose children	3
DTP3: A marker of routine immunization service delivery to children	4
MCV: Canary in the coal mine	5
HPV	6
Regional Comparison	7
Additional Vaccines	8
Appendix	9


Greece in the 'Europe' region



Overview


- A total of 11 childhood vaccines are tracked for Greece; of these, 8 reached the 90% coverage target or higher in 2025.
- Coverage of the first dose of diphtheria-tetanus-pertussis-containing vaccine (DTP1) was the same in 2025 as it was in 2024 (98%), coverage of the third dose of DTP-containing vaccine (DTP3) declined from 95% in 2024 to 94% in 2025, and coverage of the first dose of the measles-containing vaccine (MCV1) declined from 96% in 2024 to 94% in 2025.
- In 2025, the number of zero-dose children for DTP in Greece (1,000) was approximately 124% higher than the annual number proposed to achieve the IA2030 target of halving zero-dose children for DTP by 2030 (<1,000), based on a linear trajectory of decline.

Vaccine coverage (%), Greece, 2000–2025



Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

Estimated number of zero-dose children, 2000–2025 and target by 2030, Greece




Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.
 Note: The Immunization Agenda 2030 (IA2030) calls on all countries to reduce the number of zero-dose children in 2019 in half by 2030.
 Dark blue bars are the estimated number of zero-dose children in 2000–2025.
 Light blue bar is the target number of zero-dose children by 2030.
 The line and points show the yearly progress and trajectory to meet the target by 2030, based on a linear decline.

DTP1: Reaching zero-dose children

- Coverage of DTP1 stood at 98% in 2025. This is lower than in 2019 (99%) and the same as in 2024 (98%).
- The percentage of zero-dose children was 124 percentage points higher than the IA2030 target in 2025. There were approximately 1,000 zero-dose children in 2025, more than the <1,000 in 2019 but fewer than the 1,000 in 2024.
- Coverage of DTP1 in Greece (98%) was higher than the Eastern Europe and Central Asia regional average of 90% in 2025.
- DTP1-to-DTP3 dropout in 2025 was 4%, 4 percentage points higher than in 2019 (0%). Low DTP dropout rates imply good ability to provide a complete vaccine series early in life.


**DTP1 coverage and zero-dose children
over time, Greece, 2000–2025**



Dotted line shows the IA2030 target of 90% coverage
Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

DTP3: A marker of routine immunization service delivery to children


- Coverage of DTP3 stood at 94% in 2025. This is lower than in 2019 (99%) and lower than in 2024 (95%).
- The number of children vaccinated with DTP3 decreased from 82,000 in 2019 to 64,000 in 2025.
- In 2025, there were 4,000 children un- or under-vaccinated in Greece.
- In 2025, 4% of children who received DTP1 did not receive DTP3. This 4% dropout rate was 4 percentage points higher than in 2019 (0%) and 1 percentage points higher than the 2024 dropout rate (3%).
- Coverage of DTP3 in Greece (94%) was higher than the Eastern Europe and Central Asia regional average of 87% in 2025.



Dotted line shows the IA2030 target of 90% coverage
Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

MCV: Canary in the coal mine


- Coverage of MCV1 stood at 94% in 2025. This is lower than in 2019 (97%) and lower than in 2024 (96%).
- Coverage of the second dose of the measles-containing vaccine (MCV2) increased from 76% in 2019 to 83% in 2025. This leaves 4,000 children without any protection against measles and another 9,000 with only partial protection.
- In 2025, 4% of children who received DTP1 did not receive MCV1. This 4% dropout rate was 2 percentage points higher than in 2019 (2%) and 2 percentage points higher than the 2024 dropout rate (2%).
- Greece has achieved MCV1 coverage above 80% over all of the last 3 years.
- Coverage of MCV1 in Greece (94%) was higher than the Eastern Europe and Central Asia regional average of 88% in 2025.



Dotted line shows the IA2030 target of 90% coverage
 Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

HPV

- Programme coverage of HPV1 among females decreased from 64% to 63% between 2024 and 2025, and coverage of the last dose (HPVc) also decreased from 56% to 54%.
- HPVc coverage remains well below the IA2030 target of 90%.
- In 2025, approximately 20,000 females in Greece did not receive any HPV vaccination (un-vaccinated).
- Among Eastern Europe and Central Asia region peers, Greece ranked 5 out of 18 countries in HPVc coverage in 2025.




Dotted line shows the IA2030 target of 90% coverage
 Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

Regional Comparison

The chart below shows how Greece compares to other countries in the Eastern Europe and Central Asia region on DTP1, DTP3, MCV1, and HPVc coverage in 2025. The dashed line represents the regional average for each vaccine.

Coverage comparison: Greece vs. ECAR peers, 2025

Dashed line = regional average



Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

Additional Vaccines

- Coverage of HepB3 stood at 90% in 2025. This is lower than in 2019 (96%) and lower than in 2024 (92%).
- Coverage of Hib3 stood at 93% in 2025. This is lower than in 2019 (99%) and lower than in 2024 (95%).
- Coverage of IPV1 stood at 98% in 2025. This is lower than in 2019 (99%) and the same as in 2024 (98%).
- Coverage of PCVC stood at 89% in 2025. This is lower than in 2019 (96%) and lower than in 2024 (90%).
- Coverage of RotaC stood at 20% in 2025. This is the same as in 2019 (20%) and the same as in 2024 (20%).

Additional vaccine coverage (%), Greece, 2000–2025

	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
HepB3	89	90	91	92	92	93	94	95	95	95	95	95	98	98	96	96	96	96	96	96	96	96	95	93	92	90
Hib3	87	87	86	86	85	84	84	83	83	83	83	83	95	95	99	99	99	99	99	99	99	99	98	96	95	93
IPV1																99	99	99	99	99	99	99	99	99	98	98
PCVC													32	32	96	96	96	96	96	96	96	96	93	90	90	89
RotaC															20	20	20	20	20	20	20	20	20	20	20	20



Source: WHO/UNICEF estimates of national immunization coverage, 2025 revision.

Appendix

WHO/UNICEF Estimates of National Immunization Coverage (WUENIC)

Each year, WHO and UNICEF review national immunization data from Member States, including administrative and official coverage, survey estimates and contextual information, and use rules-based data triangulation approach to assess coverage. Estimates are produced independently, without borrowing data from other countries, and are not based on ad hoc adjustments. In some cases, they rely on a single source, typically nationally reported coverage. When data for a specific country-vaccine-year are unavailable, values from adjacent years are interpolated or extrapolated, and conflicting sources are assessed to determine the most reliable estimate, considering potential biases and expert opinion.

Methods:

- [Burton et al. 2009. WHO and UNICEF estimates of national infant immunization coverage: methods and processes](#)
- [Burton et al. 2012. A formal representation of the WHO and UNICEF estimates of national immunization coverage: a computational logic approach](#)
- [Brown et al. 2013. An introduction to the grade of confidence used to characterize uncertainty around the WHO and UNICEF estimates of national immunization coverage](#)

These talking points present the latest WUENIC estimates (published 15 July 2026).

Definitions of immunization terms:

- Bacillus Calmette-Guerin (BCG): vaccine against tuberculosis
- Hepatitis B birth dose, given within 24 hours after birth (HepBB)
- Diphtheria, tetanus, and pertussis vaccine, first dose (DTP1) and third dose (DTP3)
- Hepatitis B vaccine, third dose (HepB3)
- Haemophilus influenzae type B vaccine, third dose (Hib3)
- Inactivated polio vaccine, first dose (IPV1) and last dose (IPVC)
- Measles containing vaccine, first dose (MCV1) and second dose (MCV2)
- Rotavirus vaccine, last dose (RotaC)
- Pneumococcal vaccine, last dose (PCV)
- Yellow Fever vaccine (YFV)
- Meningococcal A vaccine (MengA)
- Human Papillomavirus vaccine, first dose (HPV1) and last dose (HPVc)

Additional resources: <https://data.unicef.org/resources/immunization/>